Is Mounjaro Approved for Weight Loss? Here’s What Our Endocrinologist Says

Introduction

Mounjaro (tirzepatide) is an injectable medication approved in 2024 by the Central Drugs Standard Control Organization (CDSCO) in India, for improving blood sugar management in adults with type 2 diabetes (T2DM), when used in conjunction with diet and exercise^1,2. Since its approval, tirzepatide has earned significant attention not only for its glucose-lowering effects but also for its impact on weight management^3,4. 

This article explores the pharmacologic mechanisms of tirzepatide, reviews key clinical findings, examines emerging evidence on its effect on body weight and metabolic health, and considers expert opinions on the medicine. 

Is Mounjaro Approved for Weight Loss?

Mounjaro (tirzepatide) is currently approved only for the treatment of T2DM. It is not officially approved for weight loss¹. 

However, in the United States, the Food and Drug Administration (FDA) has approved tirzepatide for weight loss under a different brand name known as Zepbound. This brand is specifically used for chronic weight management in adults with obesity or those who are overweight with a minimum of one weight-related condition (such as hypertension)⁵. 

Therefore, to answer the question, “is Mounjaro approved for weight loss?”, while the brand Mounjaro is not approved for weight loss in India, Zepbound (another brand name for tirzepatide) is approved in the U.S. for weight management, although not specifically as a weight loss drug. 

How Does Mounjaro Work?

Tirzepatide works by stimulating two natural gut hormones: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide)⁶. These hormones help regulate blood sugar, insulin levels, and appetite⁷. 

By activating both GLP-1 and GIP receptors, tirzepatide: 

• Enhances insulin secretion when blood sugar is high⁶
• Reduces glucagon levels, which helps lower glucose production⁷ 
• Slows down digestion, helping you feel full longer⁸ 
• Reduces hunger signals, which may lead to changes in eating habits⁴ 

These combined effects may support better blood sugar control and may help in weight management. Therefore, for people wondering “how does Mounjaro help you lose weight,” the answer lies in its unique ability to influence both metabolic and appetite-related pathways, leading to reduced appetite and altered eating patterns over time. 

Who Is Mounjaro Prescribed For?

Mounjaro is primarily prescribed for adults with T2DM, especially those with insulin resistance who need better blood sugar control⁹. 

Mounjaro may also be considered for patients who have obesity or metabolic syndrome, where improving insulin sensitivity and managing weight is essential. Although Mounjaro is not officially approved for weight loss in India, weight management plays a key role in managing conditions like T2DM, high blood pressure, and cardiovascular risk⁹. In such cases, Mounjaro may be used strictly under medical supervision to support overall metabolic health and long-term disease management. 

How Is Mounjaro Taken?

Mounjaro is given as an injection (once weekly), usually at the same time each week. It is injected under the skin (subcutaneously) at common injection sites including the stomach or thigh, or upper arm¹⁰. 

Note: It’s important to rotate injection sites each week to avoid irritation^10,11. 

While people often search for the “best place to inject Mounjaro for weight loss,” the injection site doesn’t influence the effectiveness of the medication as long as the site is rotated every week. 

Although Mounjaro is not officially approved for weight loss in India, clinical trials have used specific dosing schedules that have had a significant effect on weight¹⁰. The correct “Mounjaro dose for weight loss” should only be determined by a doctor based on the patient’s individual health needs. 

Additional Note: Always use Mounjaro under medical supervision to ensure safety and effectiveness. 

What Are the Reported Effects?

Patients and clinical studies have reported several noticeable changes while using Mounjaro. Commonly observed effects include: 

• Reduced appetite⁴ 
• Feeling full sooner and for longer periods after meals⁸ 

These changes may support improved portion control and less frequent cravings (or snacking), which may eventually support better weight and blood sugar management. 

However, it’s important to note that these reported effects are not guaranteed. Responses to Mounjaro can vary based on individual factors like lifestyle, medical history, and how the body reacts to treatment. Always consult your doctor for any advice. 

Mounjaro Side Effects

When using Mounjaro for diabetes management, some patients report side effects, especially during the first few weeks as the body adjusts. Commonly noted Mounjaro side effects include^6,10: 

• Nausea 
• Vomiting 
• Constipation 
• Diarrhoea 

Tips to manage the above gastrointestinal side effects of Mounjaro¹²: 

• Eat smaller, lighter meals 
• Avoid greasy or spicy foods 
• Stay well-hydrated 
• Don’t lie down immediately after eating 
• Speak to your doctor if symptoms persist/worsen 

While many people tolerate Mounjaro well, it’s important to monitor people taking Mounjaro for weight loss for side effects and consult a doctor to ensure safe and effective use. 

In my experience, when taking Mounjaro, always consult a qualified dietitian or nutritionist to review your diet plan. This helps prevent gastrointestinal discomfort, Hypoglycemia-related dizziness, and other potential complications linked to unbalanced nutrition.

Dr. Malavika Athavale, Consulting Clinical and IBS Nutritionist

What Studies Say: Mounjaro and Weight Outcomes

Clinical trials, including the SURMOUNT series, have explored the impact of tirzepatide (the active ingredient in Mounjaro) on weight management. In these studies, participants who received tirzepatide experienced significant weight reduction, depending on the dose and study duration^6,13. 

For example, in SURMOUNT-1, adults with obesity (without diabetes) lost up to 21% of their body weight over 72 weeks¹⁴. 

In comparison to other GLP-1 medications, such as semaglutide, Mounjaro showed a greater average reduction in body weight in clinical trials¹⁵. 

Important: These outcomes reflect clinical trial data and do not guarantee the same results for everyone. Weight changes depend on individual factors, including adherence to treatment, lifestyle, and overall health. 

Also Read: Mounjaro vs Zepbound: Differences, Uses, Side Effects & More

Mounjaro Cost and Availability

In India, Mounjaro is available by prescription and is primarily indicated for T2DM. Its price starts from three thousand rupees and can vary based on the dosage and the pharmacy where it’s purchased. Some insurance plans or discount programs may help reduce the cost. It’s best to check with your local pharmacy or insurance provider for specific pricing and coverage details. 

While many people search for terms like “Mounjaro price for weight loss” or “how to get Mounjaro for weight loss,” it’s important to note that the drug is not approved for weight loss in India and its use for weight management should be considered strictly under the guidance of a doctor. 

Note: Patients are strongly advised to avoid sourcing Mounjaro online without a prescription, as it should only be used under medical supervision to ensure safety and effectiveness. 

What to Know Before Using Mounjaro?

Before starting Mounjaro, it’s important to understand who it’s meant for and when it may not be appropriate: 

• Eligibility: Mounjaro is intended for adults with T2DM and may be considered in certain cases for those with obesity or metabolic syndrome, under medical guidance¹⁰. 
• Contraindications: It may not be suitable for individuals with a history of medullary thyroid cancer, pancreatitis, or severe gastrointestinal disease. It should also be avoided during pregnancy unless specifically advised¹⁰.
• Medical Supervision: This is not a self-prescribed solution. Thus, dosing, monitoring for side effects, and adjusting therapy must be done under the supervision of a qualified doctor.

Also Read: Mounjaro vs Ozempic: Our Endocrinologist Explains the Difference

Conclusion

Mounjaro is an FDA-approved medication for T2DM and, while not officially approved for weight loss in India, some patients have experienced additional metabolic benefits, including changes in appetite and weight. 

However, it is not a substitute for healthy lifestyle choices. Long-term success in managing diabetes, weight, or related conditions depends on a combination of medical guidance, balanced nutrition, regular physical activity, and consistent follow-up. 

Always consult a doctor before starting or continuing any medication like Mounjaro. Remember, safe, supervised use is key to achieving the best outcomes. 

Also Read: Mounjaro (Injection): Uses, Side Effects, Dosage, and How It Works 

Frequently Asked Questions (FAQs)

References

1. U.S. Food and Drug Administration. Drug Trials Snapshots: MOUNJARO. U.S. Department of Health and Human Services. [cited 2025 Jun 16]. Available from: https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-mounjaro 
2. Central Drugs Standard Control Organisation (CDSCO). Recommendations of the Subject Expert Committee (Endocrinology & Metabolism) meeting held on 13 August 2024 [Internet]. New Delhi: CDSCO; 2024 Aug 13 [cited 2025 Jun 17]. Available from: https://cdsco.gov.in/opencms/resources/UploadCDSCOWeb/2018/UploadCommitteeFiles/Recommendations%20Endocrinology%20%26%20Metabolism%2013.08.2024.pdf 
3. Gettman L. New Drug: Tirzepatide (Mounjaro™). Sr Care Pharm. 2023 Feb 1;38(2):50-62. Available from: https://pubmed.ncbi.nlm.nih.gov/36751934/ 
4. Heise T, DeVries JH, Urva S, Li J, Pratt EJ, Thomas MK, Mather KJ, Karanikas CA, Dunn J, Haupt A, Milicevic Z, Coskun T. Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes. Diabetes Care. 2023 May 1;46(5):998-1004. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC10154650/ 
5. U.S. Food and Drug Administration. FDA approves new medication for chronic weight management. FDA. 2023; [cited 2025 Jun 16]. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-chronic-weight-management 
6. Farzam K, Patel P. Tirzepatide [Internet]. StatPearls Publishing. 2025; [cited 2025 Jun 09]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK585056/ 
7. Liu QK. Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists. Front Endocrinol (Lausanne). 2024 Jul 24;15:1431292. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC11304055/ 
8. U.S. Food and Drug Administration. Update on FDA’s ongoing evaluation of reports of suicidal thoughts or actions in patients taking a certain type of medicines approved for type 2 diabetes and obesity. Department of Health and Human Services. [cited 2025 Jun 16]. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/update-fdas-ongoing-evaluation-reports-suicidal-thoughts-or-actions-patients-taking-certain-type 
9. Corrao S, Pollicino C, Maggio D, Torres A, Argano C. Tirzepatide against obesity and insulin-resistance: pathophysiological aspects and clinical evidence. Front Endocrinol (Lausanne). 2024 Jun 24;15:1402583. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC11228148/ 
10. U.S. Food and Drug Administration. Mounjaro (tirzepatide) injection, for subcutaneous use: Highlights of prescribing information. FDA. 2022; [cited 2025 Jun 09]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215866s000lbl.pdf 
11. Eli Lilly and Company. Mounjaro Patient Booklet: patient guide to tirzepatide and the KwikPen device. March 2025; [cited 2025 Jun 16]. Available from: https://uk.lilly.com/metabolic/assets/pdf/mounjaro-patient-booklet.pdf 
12. Gorgojo-Martínez JJ, Mezquita-Raya P, Carretero-Gómez J, Castro A, Cebrián-Cuenca A, de Torres-Sánchez A, García-de-Lucas MD, Núñez J, Obaya JC, Soler MJ, Górriz JL, Rubio-Herrera MÁ. Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus. J Clin Med. 2022 Dec 24;12(1):145. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC9821052/ 
13. Jensen TL, Brønden A, Karstoft K, Sonne DP, Christensen MB. The Body weight Reducing Effects of Tirzepatide in People with and without Type 2 Diabetes: A Review on Efficacy and Adverse Effects. Patient Prefer Adherence. 2024 Feb 8;18:373-382. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC10861994/ 
14. Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A; SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022 Jul 21;387(3):205-216. Available from: https://pubmed.ncbi.nlm.nih.gov/35658024/ 
15. Müllertz ALO, Sandsdal RM, Jensen SBK, Torekov SS. Potent incretin-based therapy for obesity: A systematic review and meta-analysis of the efficacy of semaglutide and tirzepatide on body weight and waist circumference, and safety. Obes Rev. 2024 May;25(5):e13717. Available from: https://pubmed.ncbi.nlm.nih.gov/38463003/ 
16. Central Drugs Standard Control Organisation. SEC (Endocrinology & Metabolism) meeting recommendations dated 19 June 2024. Recommendations of the SEC (Endocrinology & Metabolism). New Delhi: CDSCO; 2024 Jun 19. Available from: https://cdsco.gov.in/opencms/resources/UploadCDSCOWeb/2018/UploadCommitteeFiles/Recommendations%20Endocrinology%20%26%20Metabolism%2019.06.2024.pdf  
17. Garvey WT, Frias JP, Jastreboff AM, le Roux CW, Sattar N, Aizenberg D, Mao H, Zhang S, Ahmad NN, Bunck MC, Benabbad I, Zhang XM; SURMOUNT-2 investigators. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023 Aug 19;402(10402):613-626. Available from: https://pubmed.ncbi.nlm.nih.gov/37385275/ 

Disclaimer: The information provided here is for educational/awareness purposes only and is not intended to be a substitute for medical treatment by a healthcare professional and should not be relied upon to diagnose or treat any medical condition. The reader should consult a registered medical practitioner to determine the appropriateness of the information and before consuming any medication. PharmEasy does not provide any guarantee or warranty (express or implied) regarding the accuracy, adequacy, completeness, legality, reliability or usefulness of the information; and disclaims any liability arising thereof.